Introduction

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloblastic leukemia (AML), which is characterized by unique morphology and coagulopathy (1). Patients with APL represent a marked hemorrhagic diathesis caused by disseminated intravascular coagulation (DIC) and excessive primary fibrinolysis. Introduction of all-trans retionoic acid (ATRA) has been the major breakthrough in the treatment of APL (2). Although the drug target was demonstrated after clinical use, ATRA is currently recognized as the molecular targeted therapy directed at the chimeric pro-
. In the JALSG APL92 and APL97 studies, which included ATRA plus chemotherapy followed by consolidation chemotherapy, the 5 
-year EFS were 52% and 65%, respectively (4-6). In several multicenter trials, more than 90% of APL patients treated with ATRA plus chemotherapy achieve CR and approximately 60-70% of patients have EFS (1, 3). Non-cross resistance between ATRA and chemotherapeutic drugs appears to contribute to the significant improvement in EFS. However, several major clinical problems still account for treatment failure, including early death, death during consolidation, and disease relapse. It is of importance to prevent hemorrhage and RAS during induction, because primary resistance to ATRA is an exception in newly diagnosed APL with t(15;17) (3). Initial leukocyte count more than 10×10
9 /L is a significant unfavorable prognostic factor for EFS (3, 6) . The optimal chemotherapy during induction and postremission in this high-risk group remains to be determined. Because of the excellent response with ATRA plus chemotherapy, stem cell transplantation generally is not indicated in the first CR but might be considered for the high-risk patients.
New Therapeutic Agents for Relapsed APL
About 15-25% of patients eventually relapse and are possibly refractory to further ATRA and chemotherapy (1, 3 
